This content is from: Portfolio Specialty Pharma Drugs Raise Difficult Issues Several innovative new specialty drugs have been successful at treating diseases like hepatitis, but they often do so at a steep cost. By Khadijah M. Silver December 15, 2015
Sponsored Gilead To Buy Pharmasset For $11B Biopharmaceutical company Gilead Sciences will be acquiring clinical-stage pharmaceutical company Pharmasset. November 22, 2011
This content is from: Research Health Care - Biotechnology: 2011 Third Clients say Sanford C. Bernstein & Co.’s Geoffrey Porges, in third place for a fourth straight year, is “an independent thinker” who “isn’t afraid to break from the crowd.” October 11, 2011
This content is from: Portfolio Gilead Sciences’ Miracle Drug Combination Investors stand to benefit from Gilead’s top-selling hepatitis C and HIV drugs even as the biotech company is trading at a discount. By Vitaliy Katsenelson February 23, 2016
This content is from: Portfolio Ex-FrontPoint Manager Charged With Securities Fraud Joseph Skowron III, former co-portfolio manager of FrontPoint’s health care funds, was charged with securities fraud and conspiracy to obstruct justice by the U.S. Attorney for the Southern District of New York. By Stephen Taub April 13, 2011
